证券代码：000953 证券简称：河化股份 公告编号：2024-009 广西河池化工股份有限公司 刘天佐先生在公司任职期间恪尽职守、勤勉尽责，公司董事会谨向刘天佐先 生表示诚挚的敬意与衷心的感谢！ 二、公司非独立董事补选情况 为完善公司治理结构，保证公司董事会的规范运作，根据《公司法》《公司 章程》等相关规定，经公司股东广西河池化学工业集团有限公司推荐，公司董事 会提名委员会审核，公司于2024年4月24日召开第十届董事会第十四次会议，审 议通过了《关于变更非独立董事的议案》，公司董事会同意提名魏一雪先生为公 司第十届董事会非独立董事候选人（候选人简历详见附件），并同意魏一雪先生 在当选公司非独立董事后担任公司第十届董事会副董事长、薪酬与考核委员会委 员、审计委员会委员、提名委员会委员、战略委员会委员职务，任期自公司股东 大会选举通过之日起至公司第十届董事会任期届满。该议案尚需提交股东大会审 关于变更非独立董事的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 广西河池化工股份有限公司（以下简称"公司"）于 2024年4月24日召开第 十届董事会第十四次 ...

广西河池化工股份有限公司 中兴财光华审专字（2024）第 226008 号 内部控制审计报告 中兴财光华审专字(2024)第226008号 广西河池化工股份有限公司全体股东： 中兴财光华会计师事务所 中国注册会计师：谢中梁 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求， 我们审计了广西河池化工股份有限公司（以下简称"河化股份"）2023 年 12 月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业 内部控制评价指引》的规定，建立健全和有效实施内部控制，并评价其有效 性是河化股份董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发表 审计意见，并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外，由于 情况的变化可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降 低，根据内部控制审计结果推测未来内部控制的有效性具有一定风险。 四、财务报告内部控制审计意见 我们认为，河化股份 ...

Financial Performance - The company's operating revenue for 2023 was ¥187,495,292.44, an increase of 16.74% compared to ¥160,612,375.12 in 2022[23] - The net profit attributable to shareholders for 2023 was -¥11,559,209.01, showing an improvement of 88.49% from -¥100,436,899.14 in the previous year[23] - The net cash flow from operating activities reached ¥20,925,407.23, a significant increase of 2,517.24% compared to ¥799,521.87 in 2022[23] - The basic earnings per share for 2023 was -¥0.03, improving by 88.89% from -¥0.27 in 2022[23] - Total assets at the end of 2023 were ¥281,233,757.18, a decrease of 1.91% from ¥286,706,539.83 at the end of 2022[23] - The net assets attributable to shareholders decreased by 14.44% to ¥66,599,087.68 from ¥77,839,963.09 in 2022[23] Dividend and Shareholder Returns - The company plans not to distribute cash dividends or issue bonus shares for the year[5] - The company held 4 shareholder meetings during the reporting period, ensuring equal rights for all shareholders, especially minority shareholders[88] - The annual shareholder meeting on June 1, 2023, had a participation rate of 49.82%[93] - The company has not proposed any cash dividend distribution plan for the reporting period despite having a positive profit available for distribution to shareholders[131] Revenue Trends - The company's total revenue for Q1 2023 was ¥57,808,350.06, which decreased to ¥36,181,147.45 by Q4 2023, reflecting a downward trend throughout the year[28] - The revenue from temporary business activities, such as material sales and fixed asset leasing, was ¥53,764.02 in 2023, down from ¥820,742.67 in 2022[24] - The pharmaceutical intermediates segment generated revenue of CNY 89.49 million, a significant increase of 78.07% compared to the previous year[49] - The urea business, however, saw a decline in revenue, totaling CNY 97.10 million, down 11.36% from the previous year[49] Research and Development - The company emphasizes research and development, with a dedicated team for new product development and process optimization to enhance efficiency and reduce costs[37] - The company's R&D investment increased by 42.45% to ¥6,095,720.76 in 2023, compared to ¥4,279,280.23 in 2022, representing 3.25% of operating revenue[61] - Research and development expenses increased by 42.45% to CNY 6,095,720.76, primarily due to the addition of new R&D projects[59] Market and Sales - The company’s domestic sales accounted for 79.65% of total revenue, while international sales made up 20.35%, with the latter increasing by 82.21% year-on-year[50] - The hydroxyl chloroquine side chain product achieved sales revenue of CNY 66.81 million, up 199.27% from the previous year[46] - The total sales volume of pharmaceutical intermediates increased by 12.51% to 363.63 tons in 2023[52] Operational Challenges - The company has faced uncertainty regarding its ability to continue as a going concern, as indicated by the negative net profit figures in recent years[23] - The company reported a government subsidy of ¥301,165.67 in 2023, down from ¥663,869.74 in 2022, indicating a decline in government support[29] - The urea business faced price fluctuations due to new production capacity and international energy price changes, but prices showed signs of recovery in the latter half of 2023[35] Governance and Compliance - The board of directors convened 8 meetings, maintaining strict adherence to regulations and ensuring accurate and timely information disclosure[89] - The company has established an independent financial department with a complete financial accounting system, ensuring no interference from the controlling shareholder[92] - The company has a robust information disclosure system, ensuring timely and fair access to information for all shareholders[90] Environmental and Social Responsibility - The company completed the reapplication for its pollutant discharge permit in May 2023, valid until May 11, 2028[140] - The company adheres to multiple environmental protection laws and standards during its operations, ensuring compliance with national regulations[140] - The company has been rated as an environmentally friendly enterprise in the 2023 Chongqing Environmental Credit Evaluation[148] Shareholder Relations - The company emphasizes the protection of shareholder rights and has adopted measures to enhance communication with investors[149] - The shareholders have pledged to not engage in any business that competes with the listed company and its subsidiaries after the completion of the transaction[155] - The company is currently fulfilling its commitments made during the initial public offering and refinancing processes[155]

广西河池化工股份有限公司 2023年，公司董事会依照《公司法》《证券法》《深圳证券交易所股票上市 规则》及《深圳证券交易所上市公司自律监管指引第1号——主板上市公司规范 运作》等有关法律法规、规范性文件及《公司章程》《董事会议事规则》等公司 规章制度的规定，本着对公司和全体股东负责的态度，认真履行职责，贯彻落实 公司股东大会的各项决议，不断规范公司治理、推动公司发展。现将董事会2023 年度主要工作情况报告如下： 一、2023年度公司整体经营情况 2023年，全球经济增长放缓，医药体系各项改革政策的实施，进一步加剧了 行业竞争。公司经营管理团队积极应对各种挑战，紧密围绕年初制定的工作计划 目标，认真贯彻董事会的战略部署，积极开展各项工作。 报告期内，公司实现营业收入18,749.53万元，较上年同期增长16.74%，报 告期公司实现利润总额-1,188.79万元，较上年同期减亏8,767.86万元，实现归 属于上市公司股东的净利润-1,155.92万元，较上年同期减亏8,887.77万元。由 于2022年公司对收购南松医药时形成的商誉计提了减值准备9,006.28万元，而本 报告期未发生大额减值事项，故报告期 ...

经核查独立董事郭益浩先生、薛有冰先生、李洪仪先生的任职经历以及签 署的相关自查文件，上述人员未在公司担任除独立董事以外的任何职务，也未 在公司主要股东公司担任任何职务，与公司以及主要股东之间不存在利害关系 或其他可能妨碍其进行独立客观判断的关系，因此，公司独立董事符合《上市 公司独立董事管理办法》《深圳证券交易所上市公司自律监管指引第 1 号—— 主板上市公司规范运作》中对独立董事独立性的相关要求。 广西河池化工股份有限公司董事会 2024 年 4 月 24 日 广西河池化工股份有限公司董事会 关于独立董事 2023 年度独立性情况的专项意见 根据证监会《上市公司独立董事管理办法》《深圳证券交易所股票上市规 则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运 作》等要求，广西河池化工股份有限公司（以下简称"公司"）董事会，就公 司在任独立董事郭益浩先生、薛有冰先生、李洪仪先生在 2023 年度任职的独 立性情况进行评估并出具如下专项意见： ...

关于广西河池化工股份有限公司 2023 年度非经营性资金占用及其他关联资金往来情况的 专项说明 中兴财光华审专字（2024）第 226009 号 目 录 关于广西河池化工股份有限公司 2023 年度非经 营性资金占用及其他关联资金往来情况的专项 说明 广西河池化工股份有限公司 2023 年度非经营性 资金占用及其他关联资金往来情况汇总表 1 关于广西河池化工股份有限公司 2023 年度非经营性资金占用及其他关联资金往来情况的专项说明 广西河池化工股份有限公司全体股东： 我们接受广西河池化工股份有限公司（以下简称"河化股份"）委托，根据 中国注册会计师执业准则审计了河化股份 2023 年 12 月 31 日的合并及公司资产 负债表，2023 年度合并及公司利润表、合并及公司现金流量表、合并及公司股东 权益变动表和财务报表附注，并出具了中兴财光华审会字（2024）第 226010 号无 保留意见审计报告。 根据《上市公司监管指引第 8 号——上市公司资金往来、对外担保的监管要 求》（证监会公告[2022]26 号）及《深圳证券交易所上市公司自律监管指南第 1 号——业务办理（2023 年 2 月修订）》的要求，河 ...

广西河池化工股份有限公司 中兴财光华审会字（2024）第 226010 号 | 目录 | | --- | 审计报告 | 合并及公司资产负债表 | 1-2 | | --- | --- | | 合并及公司利润表 | 3 | | 合并及公司现金流量表 | 4 | | 合并及公司股东权益变动表 | 5-8 | | 财务报表附注 | 9-97 | 审计报告 中兴财光华审会字(2024)第 226010 号 广西河池化工股份有限公司全体股东： 一、审计意见 我们审计了广西河池化工股份有限公司（以下简称"河化股份"）财务报 表，包括 2023 年 12 月 31 日的合并及公司资产负债表，2023 年度的合并及公司 利润表、合并及公司现金流量表、合并及公司股东权益变动表以及财务报表附 注。 我们认为，后附的财务报表在所有重大方面按照企业会计准则的规定编 制，公允反映了河化股份 2023 年 12 月 31 日的合并及公司财务状况以及 2023 年 度的合并及公司经营成果和现金流量。 二、形成审计意见的基础 我们按照中国注册会计师审计准则的规定执行了审计工作。审计报告的 "注册会计师对财务报表审计的责任"部分进一步阐述了我们 ...

证券代码：000953 证券简称：河化股份 公告编号：2024-007 广西河池化工股份有限公司 1、巩固公司现有主力产品市场，加强产品研发及市场开拓，提高盈利规模。 关于未弥补亏损达到实收股本总额三分之一的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 广西河池化工股份有限公司（以下简称"公司"）于 2024 年 4 月 24 日召开第十届 董事会第十四次会议及第十届监事会第九次会议，审议通过了《关于未弥补亏损达到实 收股本总额三分之一的议案》。现将具体情况公告如下： 一、情况概述 根据中兴财光华会计师事务所(特殊普通合伙)出具的公司《2023 年度审计报告》 （中兴财光华审会字（2024）第 226010 号），截至 2023 年 12 月 31 日，公司合并报表 累计未分配利润为-818,512,055.10 元，实收股本 366,122,195.00 元，公司未弥补亏 损金额超过实收股本总额三分之一。依据《公司法》及《公司章程》的相关规定，该事 项需提交公司股东大会审议。 二、未弥补亏损产生的原因 1、2019 年以前，由于主营业务长期处于持续 ...

证券代码：000953 证券简称：河化股份 公告编号：2024-004 广西河池化工股份有限公司 第十届董事会第十四次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和 完整，没有虚假记载、误导性陈述或者重大遗漏。 广西河池化工股份有限公司（以下简称"公司"）第十届董事会第十四次会议 通知于2024年4月11日以书面和电子邮件的形式发出，会议于2024年4月24日在重 庆南松凯博生物制药有限公司会议室以现场及通讯方式召开。本次会议由董事长 施伟光先生主持，会议应到董事9人，实到董事9人。会议的召集和召开程序符合 《公司法》和《公司章程》的有关规定。本次会议经过认真审议，形成如下决议： 一、审议通过了《2023年度总经理工作报告》。 全体与会董事认真审议了《2023年度总经理工作报告》，认为该报告客观、 真实地反映了公司的真实情况，反映了管理层落实股东大会和董事会各项决议、 执行公司各项制度、管理生产经营等方面所做的工作及取得的成果。 表决结果：9票同意，0票反对，0票弃权。 二、审议通过了《2023年度董事会工作报告》。 具体内容详见同日在巨潮资讯网（www.cninfo.com.cn）披露的 ...

Financial Performance - The company reported a revenue of CNY 61,917,759.50 for Q1 2024, representing a 7.11% increase compared to CNY 57,808,350.06 in the same period last year[5] - The net profit attributable to shareholders was a loss of CNY 1,159,982.77, which is an improvement of 26.10% from a loss of CNY 1,569,616.07 in the previous year[5] - Total operating revenue for Q1 2024 was CNY 61,917,759.50, an increase of 7.5% compared to CNY 57,808,350.06 in the same period last year[19] - Net profit for Q1 2024 was a loss of CNY 1,131,334.63, an improvement from a loss of CNY 1,573,833.18 in Q1 2023[20] - Total operating costs for Q1 2024 were CNY 62,984,104.32, up from CNY 58,304,382.79, reflecting an increase of 8.9%[19] - The company incurred financial expenses of CNY 800,214.51, down from CNY 973,773.75 in the previous year[19] Cash Flow and Assets - The company's cash flow from operating activities showed a net outflow of CNY 5,555,649.62, which is a 11.91% increase in outflow compared to CNY 4,964,205.21 in the previous year[5] - The company's cash and cash equivalents decreased by 16.09% to CNY 54,233,226.00, primarily due to payments for raw materials and fixed assets[10] - Cash and cash equivalents at the end of Q1 2024 totaled CNY 54,233,226.00, down from CNY 64,629,673.12 at the beginning of the period[22] - Total assets at the end of the reporting period were CNY 282,653,356.15, reflecting a 0.50% increase from CNY 281,233,757.18 at the end of the previous year[5] - The total current assets increased to 113,976,027.54 RMB from 108,962,094.22 RMB, reflecting a growth of approximately 9.2%[16] - The total liabilities decreased to CNY 200,435,127.46 from CNY 198,330,681.10 year-over-year[20] Shareholder Information - The total number of common shareholders at the end of the reporting period is 22,886[12] - Ningbo Yinyi Holdings Co., Ltd. holds 23.76% of shares, amounting to 87,000,000 shares, which are pledged[12] - Guangxi Hechi Chemical Industry Group holds 10.24% of shares, totaling 37,493,589 shares, which are also pledged[12] Inventory and Receivables - Accounts receivable increased by 42.25% to CNY 17,539,145.07, attributed to increased sales and outstanding customer payments[10] - Inventory levels rose by 35.05% to CNY 27,501,141.56, driven by production preparations[10] - Inventory increased to 27,501,141.56 RMB from 20,363,482.19 RMB, representing a rise of about 35.1%[16] Tax and Refunds - The company received tax refunds totaling CNY 807,183.25, which is a 109.43% increase compared to CNY 385,422.91 in the previous year[10] - The company received tax refunds amounting to CNY 807,183.25, compared to CNY 385,422.91 in the same period last year[22] Future Outlook and Strategic Plans - The company plans to transfer a 350,000 tons/year urea production capacity indicator for 94.5 million RMB to Yili Xin Tian Coal Chemical Co., Ltd.[14] - The company is focusing on the research, production, and sales of pharmaceutical intermediates after a major asset restructuring completed in early 2020[14] - The company is currently in discussions for external approval related to the capacity transfer, which carries some uncertainty[14] Accounting and Reporting - The first quarter report for 2024 has not been audited[23] - The company is implementing new accounting standards starting in 2024[23] - The financial statement adjustments related to the new accounting standards will be reflected in the annual report[23] - The report was released by the board of directors on April 24, 2024[23] - The report indicates that this is the first quarter of the new accounting standard implementation[23] - The company has not disclosed any financial results or key performance indicators for the first quarter[23] - Future outlook and performance guidance were not provided in the report[23] - There are no mentions of new products, technologies, market expansion, or mergers and acquisitions in the report[23]